<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">        <PMID Version="1">30214193</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1178-2013</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>13</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>International journal of nanomedicine</Title>                <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>            </Journal>            <ArticleTitle>Anticancer activity of paclitaxel-loaded keratin nanoparticles in two-dimensional and perfused three-dimensional breast cancer models.</ArticleTitle>            <Pagination>                <MedlinePgn>4847-4867</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S159942</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">Taxanes are highly effective cytotoxic drugs for progressing breast cancer treatment. However, their poor solubility and high toxicity urge the development of innovative formulations of potential clinical relevance.</AbstractText>                <AbstractText Label="Materials and methods" NlmCategory="UNASSIGNED">By using a simple and straightforward aggregation method, we have generated paclitaxel (PTX) loaded in keratin nanoparticles (KER-NPs-PTX). Their activities were tested against human breast cancer MCF-7 and MDA MB 231 cell lines in conventional two-dimensional (2D) cultures and in a dynamic three-dimensional (3D) model with perfused bioreactor (p3D). Moreover, KER-NPs-PTX activity was compared to free PTX and to PTX loaded in albumin nanoparticles (HSA-NPs-PTX). Cell viability, induction of apoptosis, and gene expression analysis were used as readouts.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">In 2D cultures, KER-NPs-PTX was able to inhibit tumor cell viability and to induce apoptosis similarly to PTX and HSA-NPs-PTX. In the p3D model, a lower sensitivity of tumor cells to treatments was observed. Importantly, only KER-NPs-PTX was able to induce a statistically significant increase in apoptotic cell percentages following 24 h treatment for MCF-7 (16.7±4.0 early and 11.3±4.9 late apoptotic cells) and 48 h treatment for MDA MB 231 (21.3±11.2 early and 10.5±1.8 late apoptotic cells) cells. These effects were supported, at least for MCF-7 cells, by significant increases in the expression of proapoptotic <i>BAX</i> gene (5.8±0.5) 24 h after treatment and of cleaved caspase 3 (CC3) protein.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">KER-NPs-PTX, generated by a simple procedure, is characterized by high water solubility and enhanced PTX-loading ability, as compared to HSA-NPs-PTX. Most importantly, it appears to be able to exert effective anticancer activities on breast cancer cells cultured in 2D or in p3D models.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Foglietta</LastName>                    <ForeName>Federica</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Drug Science &amp; Technology, University of Torino, Torino, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Spagnoli</LastName>                    <ForeName>Giulio C</ForeName>                    <Initials>GC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland, gcspagnoli@gmail.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Translational Pharmacology, CNR, Rome, Italy, gcspagnoli@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Muraro</LastName>                    <ForeName>Manuele Giuseppe</ForeName>                    <Initials>MG</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland, gcspagnoli@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ballestri</LastName>                    <ForeName>Marco</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Organic Synthesis &amp; Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guerrini</LastName>                    <ForeName>Andrea</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Organic Synthesis &amp; Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ferroni</LastName>                    <ForeName>Claudia</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Organic Synthesis &amp; Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Aluigi</LastName>                    <ForeName>Annalisa</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Organic Synthesis &amp; Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sotgiu</LastName>                    <ForeName>Giovanna</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Organic Synthesis &amp; Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Varchi</LastName>                    <ForeName>Greta</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Organic Synthesis &amp; Photoreactivity, National Research Council, Bologna, Italy, greta.varchi@isof.cnr.it.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>New Zealand</Country>            <MedlineTA>Int J Nanomedicine</MedlineTA>            <NlmUniqueID>101263847</NlmUniqueID>            <ISSNLinking>1176-9114</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>68238-35-7</RegistryNumber>                <NameOfSubstance UI="D007633">Keratins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P88XT4IS4D</RegistryNumber>                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Membr Biol. 2010 Oct;27(7):286-98</RefSource>                <PMID Version="1">21028937</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Drug Deliv Rev. 2014 Dec 15;79-80:145-54</RefSource>                <PMID Version="1">24819215</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2001 Nov 23;294(5547):1708-12</RefSource>                <PMID Version="1">11721053</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cold Spring Harb Perspect Biol. 2013 Apr 01;5(4):a008656</RefSource>                <PMID Version="1">23545416</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Mol Sci. 2016 May 23;17(5):</RefSource>                <PMID Version="1">27223283</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2011 Aug 31;13(4):R84</RefSource>                <PMID Version="1">21884573</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2010 Jul;122(1):35-43</RefSource>                <PMID Version="1">19701706</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2005 Nov 1;23(31):7794-803</RefSource>                <PMID Version="1">16172456</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2011 Jul 13;11:293</RefSource>                <PMID Version="1">21752268</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biotechnol Bioeng. 2003 Oct 20;84(2):205-14</RefSource>                <PMID Version="1">12966577</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Crit Rev Oncol Hematol. 2013 Dec;88(3):504-13</RefSource>                <PMID Version="1">23871532</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Chemother Pharmacol. 2015 Apr;75(4):659-70</RefSource>                <PMID Version="1">25596818</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Methods. 2001 Dec;25(4):402-8</RefSource>                <PMID Version="1">11846609</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nanomed Nanotechnol. 2013 Feb 18;4(2):1000164</RefSource>                <PMID Version="1">24163786</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2015 Apr;33(4):1837-43</RefSource>                <PMID Version="1">25634491</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World J Gastroenterol. 2003 Mar;9(3):442-5</RefSource>                <PMID Version="1">12632493</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mater Sci Eng C Mater Biol Appl. 2017 Apr 1;73:189-197</RefSource>                <PMID Version="1">28183597</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Res. 2017 Jun;15(6):723-734</RefSource>                <PMID Version="1">28213554</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2012 Feb 14;21(2):227-39</RefSource>                <PMID Version="1">22340595</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tissue Eng Part B Rev. 2010 Jun;16(3):351-9</RefSource>                <PMID Version="1">20092396</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Environ Res Public Health. 2016 Nov 25;13(12):</RefSource>                <PMID Version="1">27898016</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Pharm. 2018 Apr 5;540(1-2):132-149</RefSource>                <PMID Version="1">29427746</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Med Chem. 2015;22(35):4118-36</RefSource>                <PMID Version="1">26423086</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biotechnol Adv. 2014 Nov 15;32(7):1256-1268</RefSource>                <PMID Version="1">25116894</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biorheology. 2006;43(3,4):481-8</RefSource>                <PMID Version="1">16912419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomacromolecules. 2012 Jan 9;13(1):23-8</RefSource>                <PMID Version="1">22029860</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomed Mater. 2008 Jun;3(2):025007</RefSource>                <PMID Version="1">18458372</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Jan 3;8(1):1725-1736</RefSource>                <PMID Version="1">27965457</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Agric Food Chem. 2014 Sep 17;62(37):9145-50</RefSource>                <PMID Version="1">25174826</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Yao Xue Xue Bao. 2005 Dec;40(12):1099-104</RefSource>                <PMID Version="1">16496673</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Mol Cell Biol. 2007 Oct;8(10):839-45</RefSource>                <PMID Version="1">17684528</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6500-5</RefSource>                <PMID Version="1">23576741</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomaterials. 2015 Sep;62:138-46</RefSource>                <PMID Version="1">26051518</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Drug Deliv. 2010 Aug;17(6):452-65</RefSource>                <PMID Version="1">20504107</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomed Opt Express. 2016 May 25;7(6):2400-6</RefSource>                <PMID Version="1">27375954</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805</RefSource>                <PMID Version="1">1683908</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Pharm. 2017 Jun 20;525(2):313-333</RefSource>                <PMID Version="1">28416401</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomaterials. 2012 Jul;33(21):5414-22</RefSource>                <PMID Version="1">22560667</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Mater. 2015 Feb 4;27(5):903-10</RefSource>                <PMID Version="1">25504416</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2010 Jan;10(1):9-22</RefSource>                <PMID Version="1">20029421</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bioconjug Chem. 2014 Apr 16;25(4):649-55</RefSource>                <PMID Version="1">24628247</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bioeng Transl Med. 2016 Jul 05;1(1):63-81</RefSource>                <PMID Version="1">29313007</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 1997 Jan 17;70(2):214-20</RefSource>                <PMID Version="1">9009163</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int Endod J. 2016 May;49(5):471-82</RefSource>                <PMID Version="1">26016886</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomed Res Int. 2014;2014:180549</RefSource>                <PMID Version="1">24772414</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23</RefSource>                <PMID Version="1">23970019</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007633" MajorTopicYN="N">Keratins</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>                <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">keratin</Keyword>            <Keyword MajorTopicYN="N">nanoparticles</Keyword>            <Keyword MajorTopicYN="N">paclitaxel</Keyword>            <Keyword MajorTopicYN="N">perfused three-dimensional models</Keyword>        </KeywordList>        <CoiStatement>Disclosure MGM and GCS are shareholders of Cellec Biotek AG. The other authors report no conflicts of interest in this work.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30214193</ArticleId>            <ArticleId IdType="doi">10.2147/IJN.S159942</ArticleId>            <ArticleId IdType="pii">ijn-13-4847</ArticleId>            <ArticleId IdType="pmc">PMC6122896</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>